Galderma Group AG (SWX:GALD)

Market Cap	34.38B +28.6%
Revenue (ttm)	4.16B +18.0%
Net Income	486.08M +165.4%
EPS	2.05 +166.0%
Shares Out	237.41M
PE Ratio	70.78
Forward PE	43.65
Dividend	0.15 (0.10%)
Ex-Dividend Date	n/a

Volume	327,082
Average Volume	345,783
Open	155.10
Previous Close	144.80
Day's Range	151.60 - 157.70
52-Week Range	72.70 - 170.10
Beta	-0.11
RSI	57.32
Earnings Date	Mar 5, 2026

About Galderma Group AG

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes ACTINICA, Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, Mirvaso, NEMLUVIO, Relfydess, Benzac, Loceryl, and TRI-LUMA in therapeutic dermatology. ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Country: Switzerland
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: GALD

Financial Performance

In 2025, Galderma Group AG's revenue was $5.24 billion, an increase of 18.04% compared to the previous year's $4.44 billion. Earnings were $613.00 million, an increase of 165.37%.

Financial numbers in USD